Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Oppenheimer

Share on StockTwits

Equities researchers at Oppenheimer began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a note issued to investors on Tuesday, The Fly reports. The firm set an “outperform” rating and a $128.00 price target on the biopharmaceutical company’s stock. Oppenheimer’s target price indicates a potential upside of 30.71% from the company’s current price.

ALNY has been the subject of several other research reports. Barclays reissued a “buy” rating and issued a $125.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, August 7th. Piper Jaffray Companies set a $145.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 10th. Stifel Nicolaus set a $116.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Needham & Company LLC reissued a “buy” rating and issued a $135.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 31st. Finally, Bank of America assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, November 13th. They issued a “buy” rating and a $110.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $112.63.

NASDAQ ALNY traded up $5.20 during trading on Tuesday, hitting $97.93. The stock had a trading volume of 1,251,992 shares, compared to its average volume of 799,062. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.22 and a current ratio of 5.38. The stock has a market capitalization of $10.26 billion, a price-to-earnings ratio of -12.94 and a beta of 2.37. Alnylam Pharmaceuticals has a one year low of $60.27 and a one year high of $99.92. The stock has a 50 day simple moving average of $85.53 and a 200 day simple moving average of $78.20.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.17) by $0.25. The business had revenue of $70.06 million during the quarter, compared to the consensus estimate of $57.14 million. Alnylam Pharmaceuticals had a negative net margin of 485.73% and a negative return on equity of 52.88%. The firm’s quarterly revenue was up 3284.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.56) earnings per share. On average, sell-side analysts predict that Alnylam Pharmaceuticals will post -7.9 EPS for the current year.

In related news, President Barry E. Greene sold 58,913 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $89.99, for a total transaction of $5,301,580.87. Following the transaction, the president now directly owns 111,851 shares of the company’s stock, valued at $10,065,471.49. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO John Maraganore sold 49,456 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $79.45, for a total transaction of $3,929,279.20. Following the transaction, the chief executive officer now directly owns 239,449 shares in the company, valued at $19,024,223.05. The disclosure for this sale can be found here. Insiders own 3.60% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Capital Investment Advisory Services LLC purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $25,000. City Holding Co. purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at approximately $30,000. CWM LLC increased its holdings in Alnylam Pharmaceuticals by 1,571.4% during the third quarter. CWM LLC now owns 585 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 550 shares during the period. US Bancorp DE increased its holdings in Alnylam Pharmaceuticals by 70.2% during the second quarter. US Bancorp DE now owns 628 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 259 shares during the period. Finally, Price Wealth Management Inc. purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $46,000. 96.20% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Read More: Stock Symbols and CUSIP Explained

The Fly

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$3.23 Billion in Sales Expected for MGM Resorts International  This Quarter
$3.23 Billion in Sales Expected for MGM Resorts International This Quarter
$0.19 EPS Expected for Nordic American Tanker Ltd  This Quarter
$0.19 EPS Expected for Nordic American Tanker Ltd This Quarter
Desire Price Tops $0.0007 on Top Exchanges
Desire Price Tops $0.0007 on Top Exchanges
Mobile Crypto Pay Coin  Market Cap Tops $43,486.00
Mobile Crypto Pay Coin Market Cap Tops $43,486.00
Dash Market Cap Tops $482.85 Million
Dash Market Cap Tops $482.85 Million
Pure  Reaches Market Capitalization of $1,450.00
Pure Reaches Market Capitalization of $1,450.00


 
© 2006-2019 Zolmax.